Enhanced virus-specific CD8+ T cell responses by Listeria monocytogenes-infected dendritic cells in the context of Tim-3 blockade

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Ma, Cheng J ^b,d   Ren, Jun P ^b   Li, Guang Y ^b   Wu, Xiao Y ^b   Brockstedt, Dirk G ^c   Lauer, Peter ^c   Moorman, Jonathan P ^a,b   Yao, Zhi Q ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b East Tennessee State University   (United States)

^c Aduro BioTech Inc   (United States)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CELL PROTEIN; CYTOKINE; HEPATITIS C VACCINE; LIVE VACCINE; NONSTRUCTURAL PROTEIN 5B; RECOMBINANT VACCINE; T CELL IMMUNOGLOBULIN MUCIN DOMAIN 3 PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ARTICLE; BACTERIAL VIRULENCE; BIOENGINEERING; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CONSENSUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; LISTERIOSIS; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VACCINE PRODUCTION; VIRUS CELL INTERACTION;

CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LISTERIA MONOCYTOGENES; LISTERIOSIS; MALE; MEMBRANE PROTEINS; SIGNAL TRANSDUCTION; TH1 CELLS; VIRAL HEPATITIS VACCINES;

EID: 84900434031     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087821     Document Type: Article

References (50)

1. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5:558-567. (Pubitemid 41196755)
2. Gale M Jr, Foy EM (2005) Evasion of intracellular host defense by hepatitis C virus. Nature 436:399-945.
3. Dolganiuc A, Szabo G (2011) Dendritic cells in hepatitis C infection: can they (help) win the battle? J Gastroenterol. 46:432-47.
4. Auffermann-Gretzinger S, Keeffe EB, Levy S (2001) Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97:3171-3176.
5. Bowen DG, Waker CM (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436:946-952. (Pubitemid 41191670)
6. Lechner F, Wong DKH, Dunbar PR, Chapman R, Chung RT, et al. (2000) Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191:1499-1512. (Pubitemid 30257347)
7. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, et al. (2001) Determinant of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 19:1395-1406. (Pubitemid 33081515)
8. Neumann-Haefelin C, Spangenberg HC, Blum HE, Thimme R (2007) Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol. 13:4839-47. (Pubitemid 47496749)
9. Firbas C, Bernd J, Tauber E, Buerger V, Jelovcan S, et al. (2006) Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24:4343-4353.
10. Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, et al. (2008) Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 134:1385-1395.
11. Yutani S, Komatsu N, Shichijo S, Yoshida K, Takedatsu H, et al. (2009) Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci. 100:1935-1942.
12. Drane D, Maraskovsky E, Gibson R, Mitchell S, Barnden M, et al. (2009) Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIXTM vaccine. Human Vaccines. 5:151-157.
13. Inchauspe G, Major ME, Nakano I, Vitvitski L, Trépo C (1997) DNA vaccination for the induction of immune responses against hepatitis C virus proteins. Vaccine 15:853-856. (Pubitemid 27287974)
14. Simon BE, Cornell KA, Clark TR, Chou S, Rosen HR, et al. (2003) DNA vaccination protects mice against challenge with Listeria monocytogenes expressing hepatitis C virus NS3 protein. Infect. Immun. 71:6372-6380. (Pubitemid 37337696)
15. Archi T, Saito T, Major ME, Belyakov IM, Shirai M, et al. (2000) Prophylactic DNA vaccine for hepatitis C virus infection: HCV- specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in a HLA-A2.1 transgenic mouse model. Proc Natl Acad Sci USA. 97:297-302. (Pubitemid 30055825)
16. Alvarez-Lajonchere L, Shoukry NH, Gra B, Amador-Cañizares Y, Helle F, et al. (2009) Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a phase I clinical trial. J Viral Hepatitis. 16:156-167.
17. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, et al. (2003) Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A. 100:6753-6758. (Pubitemid 36666652)
18. Jeong SH, Qiao M, Nascimbeni M, Hu Z, Rehermann B, et al. (2004) Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J. Virol. 78:6995-7003. (Pubitemid 38781538)
19. Bartosch B, Dubuisson J, Cosset FL (2003) Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-642. (Pubitemid 36314658)
20. Flint M, Logvinoff C, Rice CM, McKeating JA (2004) Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J. Virol. 78:6875-6882. (Pubitemid 38781525)
21. Ezelle HJ, Markovic D, Barber GN (2002) Generation of hepatitis C virus-like particles by use of a recombinant vescicular stomatitis virus vector. J. Virol. 76:12325-12334. (Pubitemid 35304331)
22. Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, et al. (2007) Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and core proteins. Vaccine 25:1452-1463. (Pubitemid 46074294)
23. Capone S, Meola A, Ercole BB, Vitelli A, Pezzanera M, et al. (2006) A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-Ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J. Virol. 80:1688-1699. (Pubitemid 43228711)
24. Thammanichanond D, Moneer S, Yotnda P, Aitken C, Earnest-Silveira L, et al. (2008) Fiber-modified recombinant adenoviral constructs encoding HCV proteins induce potent HCV-specific T cell response. Clin. Immunol. 128:329-339.
25. Matsui M, Moriya O, Abdel-Aziz N, Matsuura Y, Miyamura T, et al. (2002) Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transducted with replication-defective recombinant adenovirus. Vaccine 21:211-220. (Pubitemid 35346816)
26. Echeverrial I, Pereboev A, Silva L, Zabaleta A, Riezu-Boj JI, et al. (2011) Enhanced T-cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology 54:28-37.
27. Zhou Y, Zhang Y, Yao ZQ, Moorman JP, Jia ZS (2012) Dendritic cell-based immunity and vaccination against hepatitis C virus infection. Immunology 136:385-96.
28. Bowen DG, Walker CM (2005) The origin of quasispecies: cause or sonsequence of chronic hepatitis C viral infection? J. Hepatol. 42:408-417. (Pubitemid 40254257)
29. Bukh J (2004) A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39:1469-1457.
30. Lindenbach BD, McKeating JA, Rice CM (2005) Complete replication of hepatitis C virus in cell culture. Science 309:623-626. (Pubitemid 41033648)
31. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, et al. (2013) Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 501:237-241.
32. Lauer P, Chow MY, Loessner MJ, Portnov DA, Calendar R (2002) Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors. J. Bacteriol. 184:4177-4186. (Pubitemid 34774298)
33. Starks H, Bruhn KW, Shen H, Barry RA, Dubensky TW, et al. (2004) Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J. Immunol. 173:420-427. (Pubitemid 38797368)
34. Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, et al. (2004) Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 101:13832-7. (Pubitemid 39298493)
35. Le DT, Dubensky TW Jr, Brockstedt DG (2012) Clinical development of Losteria monocytogenes - based immunotherapies. Semin Oncol. 39:311-322.
36. Neuenhahn M, Kerksiek KM, Nauerth M, Suhre MH, Schiemann M, et al. (2006) CD8alpha+ dendritic cells are required for efficient entry of Listeria monocytogenes into spleen. Immunity 25:619-630. (Pubitemid 44529037)
37. Crimmins GT, Herskovits AA, Rehder K, Sivick KE, Lauer P, et al. (2008) Listeria monocytogenes multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity. Proc Natl Acad Sci U S A 105:10191-10196.
38. Bahjat KS, Meyer-Morse N, Lemmens EE (2009) Suppression of cell-mediated immunity following recognition of phagosome-confined bacteria. PLoS Pathogen 5:e1000568.
39. Rollier CS, Paranhos-Baccala G, Verschoor EJ, Verstrepen BE, Drexhage JA, et al. (2007) Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 45:602-613. (Pubitemid 46450611)
40. + HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 1172:4546-2557.
41. Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, et al. (2010) Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 107:14733-14738.
42. Ma CJ, Ni L, Zhang Y, Zhang CL, Wu XY, et al. (2011) PD-1 negatively regulates IL-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages during chronic hepatitis C infection. Immunology 132:421-31.
43. Zhang Y, Ma CJ, Ni L, Wu XY, Kumaraguru US, et al. (2011) Crosstalk between PD-1 and SOCS-1 in HCV core-mediated IL-12 suppression. J. Immunol. 186:3093-103.
44. Zhang Y, Ma CJ, Jia ZS, Moorman JP, Yao ZQ (2011) Tim-3 Negatively Regulates IL- 12 production by Monocytes during Chronic Hepatitis C Infection. PLoS One 6:e19664.
45. Nijman HW, Kleijmeer MJ, Ossevoort MA, Oorschot VM, Vierboom MP, et al. (1995) Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells. J. Exp. Med. 182:163-174.
46. Kitajima T, Caceres-Dittmar G, Tapia FJ, Jester J, Bergstresser PR, et al. (1996) T cell- mediated terminal maturation of dendritic cells: loss of adhesive and phagocytic capacities. J. Immunol. 157:2340-2347. (Pubitemid 126450443)
47. Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, et al. (2006) Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Natural Medicine 12:207-213. (Pubitemid 43214747)
48. Bohnenkamp HR, Papazisis KT, Burchell JM, Taylor-Papadimitriou J (2007) Synergism of Toll like receptor induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol. 247:72-84. (Pubitemid 350019447)
49. Wenink MH, Santegoets KC, Broen JC, van Bon L, Abdollahi-Roodsaz S, et al. (2009) TLR2 promotes Th2/Th17 responses via TLR4 and TLR7/8 by abrogating the type I IFN amplification loop. J.Immunol. 183: 6960-70.
50. + Monocytes. J. Leu. Bio. 91:189-196. Diseases